Supernus Pharmaceuticals (SUPN) AI Stock Analysis

• Market Cap: $3.20B
• Dividend Yield: N/A
• Average Volume (3M): 795.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: 4.54%
• EPS Growth: -130.59%
• Country: US
• Employees: 674
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.00
• Shares Outstanding: 56,073,090
• 10 Day Avg. Volume: 985,956
• 30 Day Avg. Volume: 795,043
• PEG Ratio: <0.01
• Price to Book (P/B): 1.92
• Price to Sales (P/S): 3.01
• P/FCF Ratio: 11.64
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 0.01
• Enterprise Value/Gross Profit: 0.01
• Enterprise Value/Ebitda: 56.98
• 1Y Price Target: $60.60
• Price Target Upside: 28.23% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 2.16
• Revenue Forecast (FY): $702.59M

• Rating: 55 Neutral
• Price Target: $48.00 ▲(1.57% Upside)

Supernus Pharmaceuticals demonstrates strong product growth and a stable balance sheet, but faces profitability and cash flow challenges. The technical analysis suggests potential for recovery, while valuation metrics are currently unattractive. The earnings call provided a positive outlook, but highlighted operational losses and supply issues.

Positive Factors

Revenue Growth

Consistent revenue growth reflects strong demand for Supernus's products, indicating successful market penetration and product adoption.

Product Performance

Strong performance of key products suggests robust demand and effective market strategies, supporting long-term revenue stability.

Financial Stability

A low debt-to-equity ratio enhances financial stability, providing flexibility for future investments and growth opportunities.

Negative Factors

Operating Losses

Significant operating losses can strain financial resources and impact profitability, necessitating cost management improvements.

Supply Constraints

Supply constraints hinder growth potential and customer satisfaction, requiring resolution to meet demand and sustain sales momentum.

Decreased Cash Reserves

Reduced cash reserves limit financial flexibility and may constrain the company's ability to invest in growth or manage unforeseen expenses.

Supernus Pharmaceuticals Business Overview & Revenue Model

Company Description

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

How the Company Makes Money

Supernus Pharmaceuticals generates revenue primarily through the sale of its prescription medications. The company's key revenue streams include sales of its core products, particularly Oxtellar XR and Trokendi XR, which are marketed to healthcare providers and patients. Additionally, Supernus engages in strategic partnerships and collaborations with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on sales of co-developed products. The company's focus on expanding its product portfolio through research and development initiatives, along with potential new product launches, also contributes to its revenue generation. Supernus's earnings are further supported by its ability to navigate the complex regulatory environment for drug approvals, ensuring that its products reach the market effectively.

Supernus Pharmaceuticals Financial Statement Overview

Summary

Supernus Pharmaceuticals shows strong gross margins and low leverage, indicating financial stability. However, challenges in revenue growth and a decrease in net profit margin suggest areas for improvement. The company maintains operational efficiency and robust cash flow management, with a solid balance sheet characterized by low debt levels.

Income Statement

Supernus Pharmaceuticals has shown a mixed performance in its income statement. The company has a strong gross profit margin of 82.3% TTM, indicating efficient cost management. However, the net profit margin has decreased to 9.7% TTM from 11.2% in the previous year, reflecting pressure on profitability. Revenue growth has been negative at -0.43% TTM, signaling potential challenges in expanding sales. Despite these challenges, the EBIT and EBITDA margins remain healthy at 12.8% and 24.9% TTM, respectively, showcasing operational efficiency.

Balance Sheet

The balance sheet of Supernus Pharmaceuticals is robust with a low debt-to-equity ratio of 0.03 TTM, indicating low leverage and financial stability. The return on equity is modest at 6.2% TTM, suggesting moderate profitability relative to shareholder equity. The equity ratio stands at a healthy level, reflecting a strong capital structure. Overall, the company maintains a stable financial position with manageable debt levels.

Cash Flow

Cash flow analysis reveals a positive trajectory with a 13.8% growth in free cash flow TTM, highlighting improved cash generation capabilities. The operating cash flow to net income ratio is 0.65 TTM, indicating efficient conversion of income into cash. The free cash flow to net income ratio is nearly 1, demonstrating strong cash flow relative to earnings. These metrics suggest that the company is effectively managing its cash resources.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	192.59B	661.82M	607.52M	667.24M	579.77M	520.40M
Gross Profit	173.55B	583.91M	523.74M	580.02M	504.71M	467.94M
EBITDA	43.05M	178.28M	90.04M	153.44M	129.19M	212.40M
Net Income	-19.12M	73.86M	1.32M	60.71M	53.42M	126.95M
Balance Sheet
Total Assets	1.42T	1.37B	1.28B	1.70B	1.69B	1.50B
Cash, Cash Equivalents and Short-Term Investments	281.16B	453.61M	254.87M	461.33M	339.68M	422.53M
Total Debt	31.42B	34.27M	41.53M	437.97M	420.55M	390.33M
Total Liabilities	370.09B	332.34M	356.16M	816.30M	873.30M	759.24M
Stockholders Equity	1.05T	1.04B	921.52M	886.20M	815.85M	744.86M
Cash Flow
Free Cash Flow	44.19M	171.23M	110.53M	116.41M	125.08M	134.95M
Operating Cash Flow	44.41M	171.95M	111.08M	116.83M	127.13M	138.40M
Investing Cash Flow	42.78M	-189.87M	268.73M	-216.66M	-81.91M	-34.70M
Financing Cash Flow	6.49M	12.19M	-397.88M	-10.48M	-130.42M	3.56M

Supernus Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 47.26
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SUPN, the sentiment is Negative. The current price of 47.26 is below the 20-day moving average (MA) of 51.69, below the 50-day MA of 48.58, and above the 200-day MA of 37.87, indicating a neutral trend. The MACD of 1.08 indicates Positive momentum. The RSI at 39.70 is Neutral, neither overbought nor oversold. The STOCH value of 48.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SUPN.

Supernus Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	67 Neutral	$1.18B	9.07	18.32%	―	1.37%	-18.10%
ANIP	66 Neutral	$2.01B	―	-2.82%	―	38.68%	-160.14%
AVDL	61 Neutral	$1.85B	―	-0.32%	―	79.88%	99.60%
SUPN	55 Neutral	$3.20B	―	-1.86%	―	4.54%	-130.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALVO	48 Neutral	$1.47B	24.11	―	―	98.37%	―
PRGO	48 Neutral	$2.78B	―	-0.65%	5.55%	-2.55%	66.00%

Supernus Pharmaceuticals Corporate Events

Supernus Pharmaceuticals’ Earnings Call: Growth Amid Challenges

Supernus Pharmaceuticals’ recent earnings call painted a mixed picture for investors. While the company reported strong growth in key products and an optimistic financial outlook, these positives were overshadowed by significant operating losses and supply constraints for Onapgo. Despite these challenges, Supernus remains focused on future growth opportunities.

Supernus Pharmaceuticals Reports Strong Q3 2025 Growth

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments for central nervous system (CNS) diseases. The company has a diverse portfolio that includes approved treatments for conditions such as ADHD, Parkinson’s disease, and epilepsy.

Supernus Faces Supply Constraints Amid High ONAPGO Demand

On November 4, 2025, Supernus Pharmaceuticals announced that due to stronger than expected demand for ONAPGO, supplier constraints are impacting the company’s ability to fully meet this demand. As a result, the company is prioritizing care for patients currently on ONAPGO by pausing delivery to new patients. The company is working to build adequate inventory and resume new patient initiations as soon as possible. Additionally, Supernus reported a 52% increase in combined revenues of its four growth products in the third quarter of 2025, driven by an increase in net sales of Qelbree and GOCOVRI, and the addition of sales from ZURZUVAE and ONAPGO. The company also completed the acquisition of Sage Therapeutics, Inc. on July 31, 2025, and increased its full-year 2025 revenue guidance.

The most recent analyst rating on (SUPN) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.

Supernus Pharmaceuticals’ Real-World Study on ONAPGOTM: A Closer Look

Study Overview: Supernus Pharmaceuticals is conducting a Phase 4 observational study titled ‘Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States.’ The study aims to gather real-world data on the experiences of Parkinson’s disease patients using ONAPGOTM, highlighting its significance in understanding patient outcomes and treatment efficacy in everyday settings.

Supernus Pharmaceuticals Advances ADHD Treatment Study in Young Children

Study Overview: Supernus Pharmaceuticals is conducting a Phase 4 clinical study titled ‘A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 Years Old) With Attention-Deficit/Hyperactivity Disorder (ADHD)’. The study aims to evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in treating ADHD in young children, a significant step in addressing this condition in early childhood.

Supernus Pharmaceuticals Advances SPN-817 Study for Seizure Treatment

Study Overview: Supernus Pharmaceuticals is conducting a study titled An Open-Label Extension, One-Year, Safety, and Efficacy Study of SPN-817 in Adults With Focal Onset Seizures. The study aims to evaluate the long-term safety and efficacy of SPN-817, a promising treatment for focal onset seizures. This study is significant as it could lead to a new therapeutic option for patients with this condition.

Supernus Pharmaceuticals Advances with RENAISSANCE 2 Study on SPN-817

Study Overview: The RENAISSANCE 2 study, officially titled ‘RENAISSANCE 2: a Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures,’ aims to assess the effectiveness and safety of SPN-817 in treating focal onset seizures in adults. This study is significant as it explores a potential new treatment option for a condition that affects many individuals worldwide.

Supernus Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges

Supernus Pharmaceuticals’ recent earnings call conveyed a cautiously optimistic sentiment, highlighting robust growth in core products and a strategic acquisition that promises future expansion. However, the positive outlook was tempered by a decline in operating earnings and rising expenses.